• Title/Summary/Keyword: Cancer imaging

Search Result 1,166, Processing Time 0.028 seconds

Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer

  • Oh, Jinju;Seol, Ki Ho;Lee, Hyun Joo;Choi, Youn Seok;Park, Ji Y.;Bae, Jin Young
    • Radiation Oncology Journal
    • /
    • v.35 no.4
    • /
    • pp.349-358
    • /
    • 2017
  • Purpose: This study aimed to evaluate whether prophylactic extended-field pelvic radiotherapy (EF-PRT) yields better results than standard whole pelvic radiotherapy (WPRT) in patients with pelvic lymph node-positive cervical cancer treated with concurrent chemoradiotherapy (CCRT). Materials and Methods: A total of 126 cases of stage IB-IVA cervical cancer that had pelvic lymph node involvement in magnetic resonance imaging and were treated with CCRT between 2000 and 2016 were reviewed. None of the patients had para-aortic lymph node (PALN) metastases. The patients were classified to two groups, namely, those treated with EF-PRT, including prophylactic para-aortic radiotherapy, and those treated only with WPRT. The median dose to the PALN area in patients treated with EF-PRT was 45 Gy. All patients received concurrent cisplatin-based chemotherapy. Results: Overall, 52 and 74 patients underwent EF-PRT and WPRT, respectively. Patient characteristics and irradiated dose were not significantly different, except the dose to the para-aortic area, between the two groups. The median follow-up period was 75.5 months (range, 5 to 195 months). The 10-year cumulative recurrence rate of PALN for EF-PRT vs. WPRT was 6.9% and 10.1% (p = 0.421), respectively. The 10-year disease-free survival and overall survival for EF-PRT vs. WPRT were 69.7% vs. 66.1% (p = 0.748) and 71.7% vs. 72.3% (p = 0.845), respectively. Acute gastrointestinal complications were significantly higher in EF-PRT (n = 21; 40.4%) than WPRT (n = 26; 35.1%) (p = 0.046). Late toxicities were not significantly different in both groups. Conclusion: In this study, prophylactic radiotherapy for PALN does not have an additional benefit in patients with pelvic lymph node-positive cervical cancer treated with CCRT.

Preservation through Cloning of Superior Canine Scent Detection Ability for Cancer Screening (복제를 통한 우수한 암탐지 능력의 보존)

  • Kim, Min-Jung;Park, Jung-Eun;Oh, Hyun-Ju;Hong, So-Gun;Kang, Jung-Taek;Rhim, Sang-Hyun;Lee, Dong-Won;Ra, Jung-Chan;Lee, yeong-Chun
    • Journal of Veterinary Clinics
    • /
    • v.32 no.4
    • /
    • pp.352-355
    • /
    • 2015
  • This study was conducted to ascertain whether the scent detection ability of a donor dog having extraordinary talent in cancer detection can be conserved through cloning. A specially trained dog for colorectal cancer detection was cloned, and she was trained and tested to detect breast cancers using breath samples collected from patients and healthy volunteers. Scent detection sensitivity of the clone was 93.3% and specificity was 99.5%, similar with those of donor (91% and 99%). Furthermore, the clone successfully detected early stage of breast cancers. Therefore, superior canine scent detection ability for cancer screening could be preserved through cloning.

Application of PET/CT Volume Rendering Technique to Improve Patient Satisfaction (환자의 만족도 향상을 위한 PET/CT Volume Rendering Technique 적용)

  • Jang, Dong-Gun;Lee, Sang-ho
    • Journal of the Korean Society of Radiology
    • /
    • v.15 no.6
    • /
    • pp.877-881
    • /
    • 2021
  • Customer satisfaction is a very important factor in the Korean medical system. However, the field of medical imaging is very difficult for the general public to understand. Therefore, in this study, as a way to solve the communication problem between the medical staff and the patient, the PET/CT image was reconstructed using the Volume Rendering technique to increase patient satisfaction. VRT was performed on 360 cancer patients who had undergone PET/CT examination. As a result of a satisfaction survey on 100 patients, all 100 patients showed that the VRT image was superior to the existing image. PET/CT is not a device that observes detailed anatomical shapes, such as CT or MRI, but an image that shows a strong signal of cancer and can easily produce a VRT image. These VRT images can be expressed three-dimensionally so that the general public can easily understand them, so communication between medical staff and patients can be improved more efficiently, and it is expected that the patient's "right to know" will be satisfied.

A Case of End-stage non-small cell Lung Cancer Patient with Brain Metastasis Treated with Pembrolizumab with Integrative Medicine Therapy (Pembrolizumab과 통합의학치료로 호전된 뇌전이 동반 말기 비소세포성 폐암 환자 1례)

  • Seo, Han Gil;Jin, Yong Jae;Song, Mi Hwa;Kim, In Tae;Park, Ji Hye;Jung, Jun Suk;Cho, Sung Kyoo;Shin, Kwang Soon
    • Journal of Korean Traditional Oncology
    • /
    • v.23 no.2
    • /
    • pp.11-25
    • /
    • 2018
  • Objective: The purpose of this study is to report the case of a patient with non-small cell lung cancer (NSCLC) with Programmed cell death protein 1 (PD-1) mutation treated by Integrative Medicine Therapy (IMT). Methods: A patient with metastatic NSCLC received pembrolizumab 200mg intravenously for every 3 weeks from July 2017. Repeat cycle every 3 weeks since July 2017. The patient has been treated with Integrative Medicine Therapy (IMT) since December 2016. The tumor size was measured by computed tomography (CT) and magnetic resonance imaging(MRI). Adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: After combined treatment, the extent of proximal portion of primary tumor in the left lower lobe was decreased and disease status was stable radiologically. No evidence of newly developed metastatic lesions in the brain since May 2017. The patient did not experience any adverse event according to NCI-CTCAE ver. 5.0. Conclusion: This case study suggests that Integrative Medicine Therapy (IMT) may contribute to tumor response, in conjunction with Pembrolizumab on the treatment of patients with NSCLC.

A Case Report of Recurrent L858R Mutation Non-Small-Cell Lung Cancer with Brain Metastases Treated with Erlotinib and Traditional Korean Medicine After Failure with Gefitinib (Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례)

  • Yang, Jung-min;Jang, Kwon-jun;Hwang, Woo-seok
    • The Journal of Internal Korean Medicine
    • /
    • v.43 no.5
    • /
    • pp.838-853
    • /
    • 2022
  • Objectives: The purpose of this study is to report the case of a patient with recurrent L858R mutation non-small-cell lung cancer with brain metastases treated with erlotinib and traditional Korean medicine after gefitinib failure. Methods: The patient was treated with erlotinib beginning in November 2021, and gamma knife surgery was performed on November 8, 2021. The dose of erlotinib was 150 mg/day every four weeks. At the same time, the patient was treated with traditional Korean medicine. Tumor size and cerebral edema were measured using computed tomography and magnetic resonance imaging, respectively. Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Results: After treatment with erlotinib and traditional Korean medicine for six months, the extent of the growing nodule in the right upper lobe decreased during the first three months and remained stable for the following three months. Peritumoral edema showed an increase three months after gamma knife surgery, but partial improvement of cerebral edema was confirmed with additional traditional Korean medicine six months after gamma knife surgery. The symptoms of discomfort and physical activity gradually improved. Conclusions: This case study suggests that the combination of EGFR-TKI and traditional Korean medicine may contribute to a reduction in tumor size and cerebral edema while improving quality of life.

Photodynamic therapy with chlorin e6-induced cervical cancer cell death (Chlorin e6의 농도별 Photodynamic therapy을 통한 자궁경부암 세포의 사멸도 측정)

  • Lee, Eonjin;Choe, Se-woon
    • Proceedings of the Korean Institute of Information and Commucation Sciences Conference
    • /
    • 2022.10a
    • /
    • pp.323-325
    • /
    • 2022
  • In this paper, after administration of Chlorin e6 to kill cervical cancer cells, PDT (photodynamic therapy) using laser or LED was studied for Ce6 concentration and apoptosis by administration time. After photostimulation was applied to cervical cancer cells, qualitative and quantitative evaluation through imaging and quantitative evaluation using CCK-8 were performed. As a result of the experiment, as the concentration of Ce6 increased, a large amount of cells were killed, and it was confirmed that the Ce6+PDT test group killed more. When comparing the LED and the laser, the laser was able to kill cells only at a local location, and the LED showed the result that it was possible to kill the cells in a wide range. In addition, when irradiating a local location, such as a laser, when measuring the cell viability, it is judged to be accurate to image processing the location.

  • PDF

CT and MRI image fusion reproducibility and dose assessment on Treatment planning system (치료계획시스템에서 전산화단층촬영과 자기공명영상의 영상융합 재현성 및 선량평가)

  • Ahn, Byeong Hyeok;Choi, Jae Hyeok;Hwang, Jae ung;Bak, Ji yeon;Lee, Du hyeon
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.29 no.2
    • /
    • pp.33-41
    • /
    • 2017
  • Objectives: The aim of this study is to evaluate the reproducibility and usefulness of the images through the fusion of CT(Computed tomography) and MRI(Magnetic resonance imaging) using a self-manufactured phantom. We will also compare and analyze the target dose from acquired images. Materials and Methods: Using a self-manufactured phantom, CT images and MRI images are acquired by 1.5T and 3.0T of different magnetic fields. The reproducibility of the size and volume of the small holes present in the phantom is compared through the image from CT and 1.5T and 3.0T MRI, and dose changes are compared and analyzed on any target. Results: 13 small hole diameters were a maximum 31 mm and a minimum 27.54 mm in the CT scan and the were measured within an average of 29.28 mm 1 % compared to actual size. 1.5 T MRI images showed a maximum 31.65 mm and a minimum 24.3 mm, the average is 28.8 mm, which is within 1 %. 3.0T MRI images showed a maximum 30.2 mm and a minimum 27.92 mm, the average is 29.41 mm, which is within 1.3 %. The dose changes in the target were 95.9-102.1 % in CT images, 93.1-101.4 % in CT-1.5T MRI fusion images, and 96-102 % in CT-3.0T MRI fusion images. Conclusion: CT and MRI are applied with different algorithms for image acquisition. Also, since the organs of the human body have different densities, image distortion may occur during image acquisition. Because these inaccurate images description affects the volume range and dose of the target, accurate volume and location of the target can prevent unnecessary doses from being exposed and errors in treatment planning. Therefore, it should be applied to the treatment plan by taking advantage of the image display algorithm possessed by CT and MRI.

  • PDF

The Value of Delayed $^{18}F$-FDG PET/CT Imaging for Differentiating Axillary Lymph Nodes in Breast Cancers (유방암 환자에서 액와 림프절 진단을 위한 $^{18}F$-FDG PET/CT 지연 검사의 유용성)

  • Ji, Young-Sik;Son, Ju-Cheol;Park, Cheol-Woo
    • Journal of radiological science and technology
    • /
    • v.36 no.4
    • /
    • pp.313-318
    • /
    • 2013
  • Positron emission tomography/computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) have been used as a powerful fusion modality in nuclear medicine not only for detecting cancer but also for staging and therapy monitoring. Nevertheless, there are various causes of FDG uptake in normal and/or benign tissues. The purpose of present study was to investigate whether additional delayed imaging can improve the diagnosis to differentiate the rates of FDG uptake at axillary lymph nodes (ALN) between malignant and benign in breast cancer patients. 180 PET/CT images were obtained for 27 patients with ALN uptake. The patients who had radiotherapy and chemotherapy were excluded from the study. $^{18}F$-FDG PET/CT scan at 50 min (early phase) and 90 min (delayed phase) after $^{18}F$-FDG injection were included in this retrospective study. The staging of cancers was confirmed by final clinical according to radiologic follow-up and pathologic findings. The standardized uptake value (SUV) of ALN was measured at the Syngo Acquisition Workplace by Siemens. The 27 patients included 18 malignant and 9 ALN benign groups and the 18 malignant groups were classified into the 3 groups according to number of metastatic ALN in each patient. ALNs were categorized less than or equal 3 as N1, between 4 to 9 as N2 and more than 10 as N3 group. Results are expressed as the mean${\pm}$standard deviation (S.D.) and statistically analyzed by SPSS. As a result, Retention index (RI-SUV max) in metastasis was significantly higher than that in non-metastasis about 5 fold increased. On the other hand, RI-SUV max in N group tended to decrease gradually from N1 to N3. However, we could not prove significance statistically in malignant group with ANOVA. As a consequence, RI-SUV max was good indicator for differentiating ALN positive group from node negative group in breast cancer patients. These results show that dual-time-point scan appears to be useful in distinguishing malignant from benign.

Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT

  • Kunawudhi, Anchisa;Sereeborwornthanasak, Karun;Promteangtrong, Chetsadaporn;Siripongpreeda, Bunchorn;Vanprom, Saiphet;Chotipanich, Chanisa
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.8
    • /
    • pp.4071-4075
    • /
    • 2016
  • Background: FDG PET/CT is at an equivocal stage to recommend for staging of colorectal cancer as compared to contrast-enhanced CT (ceCT). This study was intended to evaluate the value of FDG PET/ceCT in colorectal cancer staging as compared to ceCT alone. Materials and Methods: PET/ceCT was performed for 61 colorectal cancer patients who were prospectively enrolled in the study. Three patients were excluded due to loss to follow-up. PET/ceCT findings and ceCT results alone were read separately. The treatment planning was then determined by tumor board consensus. The criteria for T staging were determined by the findings of ceCT. Nodal positive by PET/ceCT imaging was determined by visual analysis of FDG uptake greater than regional background blood pool activity. The diagnostic accuracy of T and N staging was determined only in patients who received surgery without any neoadjuvant treatment. Results: Of 58 patients, there were 40 with colon cancers including sigmoid cancers and 18 with rectal cancers. PET/ceCT in pre-operative staging detected bone metastasis and metastatic inguinal lymph nodes (M1a) that were undepicted on CT in 2 patients (3%), clearly defined 19 equivocal lesions on ceCT in 18 patients (31%) and excluded 6 metastatic lesions diagnosed by ceCT in 6 patients (10%). These resulted in alteration of management plan in 15 out of the 58 cases (26%) i.e. changing from chemotherapy to surgery (4), changing extent of surgery (9) and avoidance of futile surgery (2). Forty four patients underwent surgery within 45 days after PET/CT. The diagnostic accuracy for N staging with PET/ceCT and ceCT alone was 66% and 48% with false positive rates of 24% (6/25) and 76% (19/25) and false negative rates of 47% (9/19) and 21% (4/19), respectively. All of the false negative lymph nodes from PET/ceCT were less than a centimeter in size and located in peri-lesional regions. The diagnostic accuracy for T staging was 82%. The sensitivity of the peri-lesional fat stranding sign in determining T3 stage was 94% and the specificity was 54%. Conclusions: Our study suggested promising roles of PET/ceCT in initial staging of colorectal cancer with better diagnostic accuracy facilitating management planning.

Combination of FDG PET/CT and Contrast-Enhanced MSCT in Detecting Lymph Node Metastasis of Esophageal Cancer

  • Tan, Ru;Yao, Shu-Zhan;Huang, Zhao-Qin;Li, Jun;Li, Xin;Tan, Hai-Hua;Liu, Qing-Wei
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.18
    • /
    • pp.7719-7724
    • /
    • 2014
  • Background: Lymph node metastasis is believed to be a dependent negative prognostic factor of esophageal cancer. To explore detection methods with high sensitivity and accuracy for metastases to regional and distant lymph nodes in the clinic is of great significance. This study focused on clinical application of FDG PET/CT and contrast-enhanced multiple-slice helical computed tomography (MSCT) in lymph node staging of esophageal cancer. Materials and Methods: One hundred and fifteen cases were examined with enhanced 64-slice-MSCT scan, and FDG PET/CT imaging was conducted for neck, chest and upper abdomen within one week. The primary lesion, location and numbers of metastatic lymph nodes were observed. Surgery was performed within one week after FDG PET/CT detection. All resected lesions were confirmed histopathologically as the gold standard. Comparative analysis of the sensitivity, specificity, and accuracy based on FDG PET/CT and MSCT was conducted. Results: There were 946 lymph node groups resected during surgery from 115 patients, and 221 were confirmed to have metastasis pathologically. The sensitivity, specificity, accuracy of FDG PET/CT in detecting lymph node metastasis were 74.7%, 97.2% and 92.0%, while with MSCT they were 64.7%, 96.4%, and 89.0%, respectively. A significance difference was observed in sensitivity (p=0.030), but not the others (p>0.05). The accuracy of FDG PET/CT in detecting regional lymph node with or without metastasis were 91.9%, as compared to 89.4% for MSCT, while FDG PET/CT and MSCT values for detecting distant lymph node with or without metastasis were 94.4% and 94.7%. No significant difference was observed for either regional or distant lymph node metastasis. Additionally, for detecting para-esophageal lymph nodes metastasis, the sensitivity of FDG PET/CT was 72%, compared with 54.7% for MSCT (p=0.029). Conclusions: FDG PET/CT is more sensitive than MSCT in detecting lymph node metastasis, especially for para-esophageal lymph nodes in esophageal cancer cases, although no significant difference was observed between FDG PET/CT and MSCT in detecting both regional and distant lymph node metastasis. However, enhanced MSCT was found to be of great value in distinguishing false negative metastatic lymph nodes from FDG PET/CT. The combination of FDG PET/CT with MSCT should improve the accuracy in lymph node metastasis staging of esophageal cancer.